Cytomegalovirus in solid organ transplantation: Epidemiology, prevention, and treatment

Current Infectious Disease Reports

Volumn 14, Issue 6, 2012, Pages 633-641

  Beam, Elena ^a   Razonable, Raymund R ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Antiviral prophylaxis; Cytomegalovirus; Epidemiology; Immunologic monitoring; Preemptive therapy; Prevention strategies; Solid organ transplant

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL FEATURE; COMPOSITE GRAFT; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LABORATORY DIAGNOSIS; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; NUCLEIC ACID ANALYSIS; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VIRUS CULTURE;

EID: 84870501968     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0292-2     Document Type: Review

References (39)

1. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis. 1995;171(4):1002.
2. Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc. 2012;44(3):706.
3. Linares L, Sanclemente G, Cervera C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc. 2011;43(6):2145.
4. Kim JM, Kim SJ, Joh JW, et al. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transplant: AASLD Int Liver Transplant Soc. 2011;17(4):446.
5. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant: American Soc Transplant American Soc Transplant Surg. 2011;11(10):2181. A large single-center retrospective study describing the significant association between CMV disease and graft failure and death after liver transplantation.
6. Parsaik AK, Bhalla T, Dong M, et al. Epidemiology of cytomegalovirus infection after pancreas transplantation. Transplantation. 2011;92(9):1044.
7. Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc. 2012;44(3):694.
8. Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13(3):244.
9. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant. 2011;11(11):2453. A retrospective review of three pooled clinical trials demonstrating the lower risk of CMV infection in patients receiving everolimus, as compared with mycophenolic acid, as part of the immunosuppressive regimen.
10. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis. 2012;205(4):639. A novel observation that defects in innate immune response is a risk factor for the development of CMV disease in transplant recipients.
11. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195. This study highlights the importance of immunity in the control of CMV infection after transplantation.
12. Kotton CN, Kumar D, CaliendoAM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779. This article serves as the document of a consensus developed by experts in the management of CMV in solid organ transplant recipients.
13. Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-Time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol. 2011;34(2):157.
14. Rhee JY, Peck KR, Lee NY, Song JH. Clinical usefulness of plasma quantitative polymerase chain reaction assay: diagnosis of cytomegalovirus infection in kidney transplant recipients. Transplant Proc. 2011;43(7):2624.
15. Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation. 2011;91(2):231.
16. Mori T, Kato J, Yamane A, Aisa Y, Nakazato T, Okamoto S. Comparison of the results of quantitative polymerase chain reaction for cytomegalovirus among laboratories. JPN J Clin Hematol. 2011;52(4):204.
17. Hayden RT, Yan X, Wick MT, et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50 (2):337. This article highlights the various factors that contribute to the variability in the viral load reporting among clinical laboratories.
18. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant. 2009;9(2):258.
19. Clari MA, Munoz-Cobo B, Solano C, et al. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMVspecific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin Vaccine Immunol. 2012;19(5):791.
20. Giulieri S, Manuel O. QuantiFERON(R)-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn. 2011;11(1):17.
21. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-Analysis. Clin Infect Dis. 2011;52(3):313.
22. Snydman DR, Limaye AP, Potena L, Zamora MR. Update and review: state-of-The-Art management of cytomegalovirus infectionand disease following thoracic organ transplantation. Transplant Proc. 2011;43(3 Suppl):S1.
23. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611.
24. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in highrisk kidney transplant recipients. Am J Transplant. 2010;10(5):1228.
25. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R-kidney transplant recipients is associated with long-Term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010;90(12):1427.
26. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761. A prospective randomized multicenter clinical trial showing that extending CMV prophylaxis in lung transplant patients from 3 to 12 months resulted in significant decrease of development of CMV disease.
27. Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-Term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a singlecenter, long-Term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30 (9):990.
28. Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transplant infectious disease. 2012. A single-center observational study of planned indefinite valganciclovir prophylaxis in lung transplant recipients showing a 50% rate of discontinuation of prophylaxis mainly due to leukopenia.
29. Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012;93(1):61. A prospective randomized clinical trial in renal transplant recipients comparing preventive with prophylaxis strategy, with results showing that prophylaxis with valganciclovir significantly reduced that rate of CMV infection and disease.
30. Couzi L, Pitard V, Sicard X, et al. Antibody-dependent anticytomegalovirus activity of human gammadelta T cells expressing CD16 (FcgammaRIIIa). Blood. 2012;119(6):1418.
31. Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92(9):1063.
32. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106.
33. Helantera I, Lautenschlager I, Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int. 2011;24 (12):1170.
34. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689.
35. Myhre HA, Haug Dorenberg D, Kristiansen KI, et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation. 2011;92 (2):217.
36. Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3).
37. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11 (5):1079.
38. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256. This study provides promising data regarding the potential clinical utility of a vaccine for the prevention of CMV disease in transplant recipients.
39. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebocontrolled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290.